Archives
- 2025-10
- 2025-09
- 2025-04
- 2025-03
- 2025-02
- 2025-01
- 2024-12
- 2024-11
- 2024-10
- 2024-09
- 2024-08
- 2024-07
- 2024-06
- 2024-05
- 2024-04
- 2024-03
- 2024-02
- 2024-01
- 2023-12
- 2023-11
- 2023-10
- 2023-09
- 2023-08
- 2023-07
- 2023-06
- 2023-05
- 2023-04
- 2023-03
- 2023-02
- 2023-01
- 2022-12
- 2022-11
- 2022-10
- 2022-09
- 2022-08
- 2022-07
- 2022-06
- 2022-05
- 2022-04
- 2022-03
- 2022-02
- 2022-01
- 2021-12
- 2021-11
- 2021-10
- 2021-09
- 2021-08
- 2021-07
- 2021-06
- 2021-05
- 2021-04
- 2021-03
- 2021-02
- 2021-01
- 2020-12
- 2020-11
- 2020-10
- 2020-09
- 2020-08
- 2020-07
- 2020-06
- 2020-05
- 2020-04
- 2020-03
- 2020-02
- 2020-01
- 2019-12
- 2019-11
- 2019-10
- 2019-09
- 2019-08
- 2019-07
- 2018-07
- 
                
          br Materials and Methods br Results In the Base2023-08-12  Materials and Methods Results In the Base Analysis (53% of patients having access to the ALK test in both Current and Alternative Scenarios), a total of 16,583 patients were tested of whom 1,252 were assumed to be ALK-positive. A more extensive use of Ventana in the Alternative Scenario determ 
- 
                
          During myeloid cell maturation expression of LO mRNA and2023-08-11  During myeloid cell maturation, expression of 5-LO mRNA and protein is strongly induced (60–130-fold) by calcitriol (1,25(OH)2D3) and transforming growth factor-β (TGFβ) [6,7]. The upregulation of 5-LO mRNA transcription is mainly due to transcript elongation and mRNA maturation [8,9]. Interestingly 
- 
                
          br Increased blood ATX and LPA in2023-08-11  Increased blood ATX and LPA in liver fibrosis Although previous in vitro findings have suggested a link between LPA and liver fibrosis in vivo, whether LPA plays a primary role in the pathogenesis of liver fibrosis has remained uncertain. No phenotypic changes in livers of LPA receptor-deficient 
- 
                
          What can we learn about the anticancer therapeutic efficacy2023-08-11  What can we learn about the anticancer therapeutic efficacy of Aurora kinase inhibitors from our experience with the Bcr-Abl inhibitors and the long term clinical consequence of their use in treating leukemias? As discussed, all Aurora kinase inhibitors developed to date are ATP-competitive inhibito 
- 
                
          br Materials and methods br Results2023-08-11  Materials and methods Results Discussion In the present study, we found that SSTR2, SSTR5, and DA2R proteins are expressed in ACTH-positive dihydrofolate reductase in healthy canine pituitary glands, with particularly high positive cell ratios in the intermediate lobes. Somatostatin has be 
- 
                
          In a study highlighted the usefulness of2023-08-11  In 2010, a study highlighted the usefulness of arginase-1 as a sensitive and specific marker of hepatocytic differentiation for diagnostic pathology [9]. Subsequent studies have validated the high sensitivity and specificity of arginase-1, in particular its added value in evaluating poorly different 
- 
                
          br Implications for cancer ROS have a2023-08-11  Implications for cancer ROS have a long history of being involved in the development and progression of cancer and increased ROS level is considered as a hallmark of many tumors [76], [77]. Initially, it was thought that ROS would serve as chemical mutagens that would indiscriminately damage cel 
- 
                
          MiR has already been implicated in the protective effects2023-08-11  MiR-21 has already been implicated in the protective effects of Res on lung fibrosis, but the molecular mechanisms are underexplored. Our results showed a clear increase of activation protein 1 (AP-1) activity after TGF-β treatment, which was suppressed by Res in a dose-dependent manner, suggesting 
- 
                
          Most human diseases e g cancer2023-08-11  Most human diseases (e.g., cancer, diabetes, and neurodegenerative diseases) are complex and multifactorial. Several investigations in the literature focused on new multi-target drug development, which implies active pharmacophores incorporation in one scaffold (Meunier, 2008, Lazar et al., 2004, Te 
- 
                
          Using this cheese mimicking matrix we screened the antifunga2023-08-11  Using this cheese-mimicking matrix, we screened the antifungal activity of 44 LAB fermented milk-based products and 23 LAB isolates used as protective cultures against 4 fungal targets. The LAB were obtained from the culture collections of CIRM-BIA (Centre International de Ressources Microbienne-Bac 
- 
                
          The current antifungal pipeline contains2023-08-11  The current antifungal pipeline contains several categories of compounds at different stages of development [1], [9], [10], [96]. In Table 1 we summarize the most promising antifungal molecules that are in preclinical and in clinical development. Several compounds in the pipeline are derivatives of 
- 
                
          Numerous epidemiological studies document fewer cardiovascul2023-08-11  Numerous epidemiological studies document fewer cardiovascular events and increased survival of non-CKD individuals treated with angiotensin-converting enzyme inhibitors/angiotensin receptor blockers (ACEI/ARBs) [8], [9]. By contrast, there are few studies of cardiovascular benefits of interruption 
- 
                
          br Prostate cancer and resistance2023-08-11  Prostate cancer and resistance to AR targeting treatment The AR plays a pivotal role in the development, differentiation, homeostasis and secretory function of the normal prostate (Wilson, 2011). The AR is also a key player in many phases of prostate carcinogenesis (Huggins et al., 1941, Scher an 
- 
                
          Moreover a multiple regression analysis using2023-08-11  Moreover, a multiple regression analysis using the 1-year MMSE score as a dependent variable was conducted. The result showed that serum mtep levels at admission did not affect the MMSE score 1 year later (β = 0.10, p = 0.639). Discussion In this study, serum Aβ42 levels were significantly lower 
- 
                
          WM-2474 br Current therapies for metabolic diseases2023-08-11  Current therapies for metabolic diseases Inborn errors of metabolism caused by deficiency of particular enzymes due to loss of function mutations or deletions have been treated by decreasing the intake of the enzymatic substrate, supplementation with an essential cofactor or vitamin, increasing m 
15300 records 311/1020 page Previous Next First page 上5页 311312313314315 下5页 Last page